The authors assume that the improved anti-tumor effect of their pHPMA conjugate is associated with multivalency and subsequent PD-L1 crosslinking that causes its lysosomal degradation, along with an enhanced permeability and retention (EPR) effect arising from large polymer size (55). The gene discussed is CD274; the disease is neoplasm.